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With renewed calls for malaria eradication, next-
generation antimalarials need be active against
drug-resistant parasites and efficacious against
both liver- and blood-stage infections. We screened
a natural product library to identify inhibitors of
Plasmodium falciparum blood- and liver-stage prolif-
eration. Cladosporin, a fungal secondary metabolite
whose target and mechanism of action are not
known for any species, was identified as having
potent, nanomolar, antiparasitic activity against
both blood and liver stages. Using postgenomic
methods, including a yeast deletion strains collec-
tion, we show that cladosporin specifically inhibits
protein synthesis by directly targeting P. falciparum
cytosolic lysyl-tRNA synthetase. Further, clado-
sporin is >100-fold more potent against parasite
lysyl-tRNA synthetase relative to the human enzyme,
which is conferred by the identity of two amino acids
within the enzyme active site. Our data indicate that
lysyl-tRNA synthetase is an attractive, druggable,
antimalarial target that can be selectively inhibited.
INTRODUCTION
Malaria is a significant health problem, with 225 million annual
cases and nearly 3.2 billion people at risk (WHO, 2010). Control
and treatment of this disease is compounded by a lack of an
effective vaccine. In addition, the emergence of multidrug-resis-
tant parasites has compromised efficacy of many of the frontline
chemotherapy treatments. Although there are many effective
drugs (Burrows et al., 2011), endoperoxides are the only drug654 Cell Host & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevierclass for which clinically significant resistance has not been re-
ported (Eastman and Fidock, 2009). However, endoperoxides,
like many antimalarials, are inactive against the asymptomatic
malaria liver stages. To ensure continued malaria control, with
an aim for eradication, next-generation antimalarials are required
to be active against multidrug-resistant parasites and efficacious
against liver- and blood-stage infections.
Traditional drug discovery efforts have revolved around high-
value targets identified for their essentiality in the parasite.
However, finding targets that are essential for blood and liver
malarial stages has been technically challenging, and few inhib-
itors with these desirable properties are known because of the
difficulties associated with simultaneously demonstrating that
a target is essential to support viability in both blood and
exoerythrocytic stages. An alternative approach to target
discovery is to first find compounds with promising activity in
phenotypic cell-based screens (Gamo et al., 2010; Guiguemde
et al., 2010; Plouffe et al., 2008) and to then determine their
mechanism of action through the identification of their specific
targets (reviewed in McNamara and Winzeler, 2011). Successful
validation of a target from this latter approach provides a proof of
concept for small-molecule inhibition and supports continued
drug discovery based on rational design of the hit compound.
In order to discover targets for both blood and liver stages, we
performed a screen to identify inhibitors of P. falciparum blood-
and liver-stage proliferation with a natural product library. Clado-
sporin, a fungal secondary metabolite whose primary target and
mechanism of action are not known for any species, was identi-
fied as having potent, nanomolar, antiparasitic activity in both
blood and liver stages. A member of the isocoumarin class,
cladosporin is produced by various fungal genera such as
Cladosporium, Aspergillus, Eurotium, and Chaetomium (Scott
et al., 1971). It has been previously reported to have antifungal
(Scott et al., 1971), insecticidal (Grove and Pople, 1981), and
antibacterial properties (Anke, 1979) as well as plant growth
regulatory effects (Springer et al., 1981) and anti-inflammatoryInc.
Figure 1. Haploinsufficiency Profiling of Cladosporin Identifies the
KRS1
(A) Chemical structure of cladosporin.
(B) HIP analysis of cladosporin at 110 mM. See also Figure S1. Heterozygous
strains deleted for essential genes are represented by gray boxes, and strains
deleted for nonessential genes are represented by black dots. The deletion
strain corresponding to the heterozygous krs1/KRS1 strain is labeled.
(C) Alignment of two additional, independent cladosporin HIP experiments
showing reproducibility of the KRS1 strain hypersensitivity.
(D) Cladosporin is the only substance among a diverse collection of 1,800
compounds tested by HIP profiling that significantly affects the heterozygous
KRS1 strain. Sensitivity was calculated as a logarithmic ratio of the relative
abundance of any given strain in the treated versus untreated samples and
corrected for outliers. The z score couples the sensitivity score to a value
proportional to the variation in sensitivity of any HIP strain across the 1,800
diverse compounds tested, thus allowing the identification of nonspecific
frequent hitters. For more information, refer to the Supplemental Experimental
Procedures.
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Cladosporin Selectively Targets P. falciparum Krs1responses in mouse lung tissue (Miller et al., 2010). Using both
traditional and systems biology approaches, we show here
that cladosporin potently and specifically inhibits cytosolic
lysyl-tRNA synthetase in Plasmodium spp. In addition, we
show that cladosporin is highly selective for the parasite enzyme
and that selectivity is in part conferred by the amino acid identity
at two key residues in the ATP binding pocket.
RESULTS
A Natural Product Screen Identifies Cladosporin with
Potent Antiplasmodial Activity
Small molecules with activity against P. falciparum blood-stage
parasites were previously identified in a phenotypic screen
against a natural product library (Plouffe et al., 2008). Out of
the 12,000 natural products, 275 compounds inhibited parasite
growth with 50% inhibitory concentration (IC50) values in the
submicromolar range. These hits were further screened by
a high-content image-based assay to determine their ability to
block in vitro P. yoelii liver-stage development (Meister et al.,
2011). Cladosporin (Figure 1A) demonstrated exceptional
growth-inhibitory activities against both blood- and liver-stage
parasite forms (IC50 40–90 nM) while having little effect on
the growth or viability of HepG2-CD81 cells (>10 mM) or other
human cell lines (Table 1). The high selectivity index of clado-
sporin against Plasmodium parasites compared to mammalian
cells (IC50/CC50R 111), as well as its equipotent activity against
a diverse collection of multidrug-resistant Plasmodium lines
(Table 1) and cidal action (see Table S1 available online), sug-
gested that further investigation was warranted.
Chemogenomic Profiling Reveals that Cladosporin
Targets Yeast Lysyl-tRNA Synthetase
We next sought to discover the target of cladosporin. Clado-
sporin demonstrated high micromolar inhibition against the
model yeast, S. cerevisiae, although activity varied slightly due
to compound batch and the growth media conditions (summa-
rized in Table S2). In rich growth media, cladosporin displays
a 30% inhibitory concentration (IC30) of 110 mM, making it a suit-
able compound for haploinsufficiency profiling (HIP) assay
(Giaever et al., 1999). The HIP target discovery assay is based
on a genome-wide collection of heterozygous knockout yeast
strains, each of which contains a marked gene deletion (Giaever
et al., 2002; Winzeler et al., 1999). It has been shown that hetero-
zygous diploid strains that bear a deletion in one copy of a small
molecule’s target gene show increased sensitivity to that small
molecule relative to those strains that have two copies of the
gene (Giaever et al., 1999). This is a likely consequence of
decreased expression of the target in the heterozygous diploid
strain. Each of these strains also carries a distinct 20 base pair
DNA barcode that can be PCR amplified and quantified in
competitive growth assays using microarrays containing the
barcode complements. As each barcode is linked to a specific
strain, barcodes that disappear over time in the presence of
a small molecule reveal the identity of the molecular target of
the small molecule.
Three independent HIP assays reproducibly identified the
heterozygous lysyl-tRNA synthetase (krs1/KRS1) knockout
strain as being the only strain in the collection of 5,803 totalCell Hstrains (covering 95% of the genome) that was hypersensitive
to cladosporin (Figures 1B and 1C). Because strains that bear
deletions in drug pumps or other proteins that attenuate the
action of small molecules often also show haploinsufficiency,
we also assessed whether the krs1/KRS1 strain is ubiquitously
sensitive. Historical profiling of 1,800 compounds (our unpub-
lished data) revealed that the krs1/KRS1 strain was exclusively
sensitive to cladosporin (Figure 1D), indicating a high degree of
selectivity for cladosporin. KRS1 is a nonredundant and essen-
tial gene in yeast and functions to load lysine onto the corre-
sponding tRNA molecule for protein translation (Mirande and
Waller, 1988).
Overexpression of KRS1 Decreases Cladosporin
Antifungal Activity
To further test if cladosporin specifically inhibits lysyl-tRNA
synthetase, KRS1 was placed downstream of a Gal1 promoter
and transformed into wild-type yeast. The same was done for
genes encoding isoleucyl-tRNA synthetase (IlS1), glutamyl-
tRNA synthetase (GLN4), and threonyl-tRNA synthetaseost & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevier Inc. 655
Table 1. Cladosporin Activity against Plasmodium Blood and
Liver Stages and Human Cell Lines
Strain or Cell Line
Plasmodium Activity Cell Line
IC50 (nM) CC50 (nM)
3D7a 45.4 ± 6.0
Camp Ra 77.9 ± 3.2
D10a 89.6 ± 11.4
D6a 72.1 ± 3.1
K1a 80.1 ± 10.3
NF54a 87.9 ± 5.3
FCBa 66.7 ± 4.9
FCR3a 57.4 ± 10.8
HEp2b 9,666 ± 2,200
HeLab 74,285 ± 18,830
HepG2b 43,568 ± 25,080
Huh7b >100,000
HepG2-CD81b >10,000
P. yoelii liver schizontc 39.1 ± 18.4
Dd2 clone1 62.5 ± 3.5
Cladosporin-RDd2 clone#1a 377.1 ± 31.4
Cladosporin-RDd2 clone#2a 389.5 ± 39.6
Cladosporin-RDd2 clone#3a 374.7 ± 54.0
aIC50 determined by the 72 hr SYBR Green cell proliferation assay.
bFifty percent cytotoxic inhibitory concentration (CC50) was determined
by CellTiter-Glo viability assay.
cIC50 based on the mean parasite area calculated in the high-content
screen.
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Cladosporin Selectively Targets P. falciparum Krs1(THS1). These strains were subsequently tested for growth
defects in the presence of serially diluted cladosporin concentra-
tions using galactose as a sole carbon source to drive promoter
activity. Only the transgenic strain harboring the plasmid with the
KRS1 gene conferred increased cladosporin resistance (2.2-fold
shift), whereas the transgenic strains expressing other amino-
acyl-tRNA synthetases (AARSs) exhibited no change in their
sensitivity to cladosporin (Figure 2A). In the absence of clado-
sporin, all strains grew at an equal rate and concurrently reached
the same final OD600, indicating the overexpression constructs
did not have a discernible effect on growth.
Cladosporin Resistance in Yeast Is Mediated by
Mutations in the Active Site of Krs1
To further strengthen the observed genetic link between the
S. cerevisiae lysyl-tRNA synthetase (ScKrs1) and cladosporin,
we examined mutations that confer cladosporin resistance in
yeast. Yeast cells weremutagenizedwith ethylmethanesulfonate
and then selected against 50 mM cladosporin, a concentration
known to completely inhibit growth of wild-type strains in
synthetic complete media (Table S2). Direct sequencing of the
KRS1 gene in 37 clones revealed nonsynonymous mutations in
ten of these clones (Figure 2B and Figure S2A).
To better understand the significance of these mutations, we
undertook homology modeling. The crystal structures of lysyl-
tRNA synthetase from human (Guo et al., 2008) and two bacteria
(Sakurama et al., 2009) have been published, and comparison
reveals a high degree of structural conservation (Figure S2B).656 Cell Host & Microbe 11, 654–663, June 14, 2012 ª2012 ElsevierWe took advantage of this conservation and used the human
crystal structure as a template to generate a ScKrs1 homology
model. The ScKrs1 model predicted that the identified muta-
tions, Ile567Val (one strain), Gly551Ser (two strains), and
Thr340Ile (seven strains), map to or near the binding pocket for
ATP in ScKrs1 (Figures 2B and 2C and Figure S2A). Backcross-
ing of the ten selected mutants to isogenic wild-type strains of
the opposite mating type and subsequent resistance assays re-
vealed that all mutations were dominant. Subcloning of each of
the mutated KRS1 genes into a low copy plasmid and reintro-
duction into the wild-type strain was sufficient to confer
increased resistance to cladosporin (5-fold increase), indi-
cating that second-site mutations did not contribute to resis-
tance. We conclude that the mutated KRS1 gene is responsible
for resistance in S. cerevisiae and that the resistance phenotype
is dominant to the wild-type allele (Figure 2D).
Amplification of the Lysyl-tRNA Synthetase Locus
Confers Resistance in Parasites
To establish target conservation inP. falciparum, we evolved cla-
dosporin-resistant parasites (Table 1 and Tables S3 and S4) with
hopes that the parasites would acquire resistance mutations in
the target gene. The genomes of the cladosporin-sensitive
parental clone and cladosporin-resistant clones were compared
using a microarray that has the capacity to reveal most genomic
changes that are acquired by the resistant strains, including
copy number variants, deletions, small insertion/deletion events,
and single-nucleotide polymorphisms (Dharia et al., 2009). Since
background mutations may appear at a low frequency, the
selection was run in triplicate in order to distinguish resistance-
conferring mutations from randommutations. Genome scanning
revealed that each of the independent clones had acquired copy
number variants that shared six genes in a syntenic region
of chromosome 13: MAL13P1.253, PF13_0263, PF13_0264,
MAL13P1.254, and MAL13P1.255 and PF13_0262, encoding
the cytoplasmic lysyl-tRNA synthetase (PfKrs1), the ortholog of
KRS1 (Figure 3A and Table S3). Careful examination of the
hybridization data showed that none of the other 5,500 genes
weremutated in all three clones and that the only genomic differ-
ences between the sensitive and mutant lines were the copy
number variants that encompassed PfKrs1.
Cladosporin Blocks De Novo Protein Biosynthesis in
P. falciparum
Although the high amino acid sequence conservation between
the fungal and plasmodial enzymes (Figure S2A) suggests that
cladosporin is likely targeting cytoplasmic lysyl-tRNA synthetase
in both species, it is possible that one of the other genes in the
amplification event could encode the target. Because inhibition
of cytoplasmic lysyl-tRNA synthetase is expected to impair
protein biosynthesis, incorporation of radioactive amino acids
was investigated in cladosporin-treated parasites (Figure 3B).
Treatment with cladosporin, or known protein synthesis inhibi-
tors, anisomycin and cycloheximide, caused a rapid, and
comparable, drop-off in incorporation of radiolabeled amino
acids and indicated protein synthesis inhibition. In contrast, me-
floquine and artemisinin, antimalarial drugs with unrelatedmech-
anisms of action, did not diminish radioisotope incorporation, as
previously shown (Rottmann et al., 2010).Inc.
Figure 2. Krs1 Target Validation by Overex-
pression Analysis and Chemical Mutagen-
esis of S. cerevisiae
(A) Cladosporin specificity was evaluated in strains
overexpressing the following aminoacyl-tRNA
synthetase genes: lysine (KRS1), glutamine
(GLN4), isoleucine (ILS1), and threonine (TRS1).
KRS1 overexpression confers a 3-fold increase in
cladosporin resistance, whereas no change in
cladosporin potency was observed in strains
overexpressing the other synthetases.
(B) Schematic view of the S. cerevisiae lysyl-tRNA
synthetase (ScKrs1) protein domain organization.
Resistance-conferring mutations (asterisks) are
labeled and frequency of mutation provided in
parentheses.
(C) The ATP/lysine binding pocket of the ScKrs1
homology model (gray) is shown. See also Fig-
ure S2. The distance (given in angstroms [A˚])
between the three mutated residues (stick repre-
sentations) and atoms in the ATP molecule is
indicated next to the dashed lines.
(D) Expression of the ScKrs1 mutants Thr340Ile
(Krs1T340I), Gly551Ser (Krs1G551S), Ile567Val
(Krs1I567V) shifted cladosporin IC50 values 5.3-
fold compared to an empty vector control strain,
whereas overexpression of wild-type ScKrs1
(Krs1WT) showed a 3.3-fold shift (comparable shift
to that in A).
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in P. falciparum
Malaria parasites have two lysyl-tRNA synthetases, one of which
is targeted to the apicoplast (PF14_0166), a specialized subcel-
lular organelle involved in fatty acid and isoprenoid biosynthesis,
while the other one is targeted to the cytoplasm (PF13_0262).
The apicoplast is essential to parasite viability, and inhibition
of protein synthesis in this organelle yields a characteristic
‘‘delayed death’’ phenotype in which parasite death is observed
one generation after drug treatment. Known apicoplast inhibitors
include mupirocin, which targets the apicoplast-targeted
isoleucyl-tRNA synthetase (Istvan et al., 2011); tetracycline
(Goodman et al., 2007); azithromycin (Sidhu et al., 2007); and
the apicoplast 23S ribosomal RNA inhibitor clindamycin (Dharia
et al., 2009). To distinguish between these two potential targets,
P. falciparum parasites were synchronized to the ring stage,
treated with cladosporin, and the maturation of the parasite
monitored over two life cycles. Parasites treated with clado-
sporin did not exhibit a delayed death phenotype and quickly ar-
rested in the metabolically active trophozoite stage (Figure 3C).
The phenotype of cladosporin-treated parasites is indistinguish-
able from that of anisomycin, another eukaryotic protein
synthesis inhibitor, and supports the notion that both have the
same mechanism of action. In contrast, clindamycin, which
specifically inhibits protein biosynthesis in the apicoplast, did
not diminish growth until the end of the second blood-stage
life cycle (Figure S3). Although these results do not preclude cla-
dosporin as also targeting the apicoplast lysyl-tRNA synthetase,
these data show that cladosporin is a fast-acting agent that
shows the same characteristics as other known cytoplasmic
protein synthesis inhibitors.Cell HCladosporin Is a Potent and Selective Inhibitor of
P. falciparum Lysyl-tRNA Synthetase
To confirm that cladosporin is an inhibitor of PfKrs1, direct
biochemical assays were performed on recombinant protein.
PfKrs1 activity was assayed in the presence or absence of the
corresponding lysine-tRNA (tRNALys) substrate, and synthetase
activity was measured using a Transcreener adenosine mono-
phosphate (AMP) assay. This assay is a far-red, competitive fluo-
rescence polarization immunoassay that detects the reaction
product, AMP. Cladosporin possessed a half inhibitory concen-
tration of 61 nM against PfKrs1 (Figure 4A), which is comparable
to its activity in cellular screens (IC50 40–90 nM; Table 1). As ex-
pected, no activity was observed in the absence of exogenous
tRNALys. The agreement between the biochemical and biological
inhibition constants further supports the notion that lysyl-tRNA
synthetase is the primary target within the cell.
Our data show that cladosporin has relatively little activity on
human cells, including the HepG2-CD81 cells used in the
hepatic-stage screen (Table 1). To confirm that cladosporin is
selective for PfKrs1, the human counterpart was assayed. Re-
combinant human lysyl-tRNA synthetase was assayed as
described above. As predicted, cladosporin activity was only
weakly detected at the high micromolar ranges for human Krs1
(Figure 4B). These data reinforce the notion that cladosporin
specifically and selectively targets P. falciparum lysyl-tRNA
synthetase.
Structural Basis for Selectivity and Specificity in
Plasmodium Krs1
The S. cerevisiae and P. falciparum amino acid sequences share
a high degree of identity to the human protein (yeast 58.3%,ost & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevier Inc. 657
Figure 3. P. falciparum Acquires Copy Number Variants in Lysyl-tRNA Synthetase and Has Protein Synthesis Defects in the Presence of
Cladosporin
(A) Whole-genome analysis of cladosporin-resistant P. falciparum clones on a high-density DNA tiling microarray revealed that a common gene locus on
chromosome 13 was amplified in each clone. Six genes were shared by all amplification events: lysyl-tRNA synthetase (PF13_0262), small nuclear ribonu-
cleoprotein (MAL13P1.253), a conserved Plasmodium protein of unknown function (PF13_0263), ubiquitin-activating enzyme E1 (PF13_0264), a conserved
Plasmodium protein of unknown function (MAL13P1.254), and N6-adenine-specific methylase (MAL13P1.255). An enhanced probe-by-probe analysis of this
locus is shown for each clone, and common genes are shaded green. The lysyl-tRNA synthetase gene (asterisk) is present in all amplification events. See also
Table S3.
(B) Mixed erythrocytic-stage parasites were treated for 1 hr with cladosporin, artemisinin (ART), mefloquine (MFQ), anisomycin, or cycloheximide over a five-log
range of drug concentrations to determine their effect on 35[S]-cysteine/methionine incorporation. Radioactive counts were normalized to untreated cells, and
each data point was plotted as the mean of two experiments performed in triplicate. Error bars represent the standard deviation.
(C) The specific time of action for cladosporin in erythrocytic-stage parasites was determined by treating double-synchronized parasites (6 hr interval) and
monitoring the cultures over a 60 hr period. The morphology of untreated parasites (–) and parasites treated with 400 nM cladosporin (+) were monitored by
Giemsa-stained thin blood smears for one complete 48 hr life cycle (12 hr, ring; 24 hr, trophozoite; 36 hr, early schizont; 48 hr, mature schizont) and the first 12 hr of
the second generation. Representative images are shown for each time point. Controls are shown in Figure S3.
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Cladosporin Selectively Targets P. falciparum Krs1plasmodium 53.4%), and the homology model could accommo-
date both primary sequences into the human template with high
confidence. According to the predicted models, 30 of 36 amino
acids within a 5 A˚ radius of the ATP/lysine-binding site are
conserved between S. cerevisiae and P. falciparum. Using an
in silico docking approach it was possible to model cladosporin
into the ATP-binding pocket in an energetically favorable mode,
mimicking that of ATP (Figure 4C). Residues Asn335 andGlu328,
which hydrogen bond to ATP, are also predicted to hydrogen658 Cell Host & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevierbond with the hydroxyl groups of cladosporin. The accuracy of
this prediction was validated biochemically. Characterization of
the recombinant PfKrs1 revealed that lysine had no effect on
cladosporin inhibition (Figure S4A), whereas increasing concen-
trations of ATP in the reaction buffer significantly reduced clado-
sporin inhibition (Figure S4B). This was corroborated by the
inability of exogenous lysine in culturing media to affect clado-
sporin potency against yeast cells (Table S5). Taken together,
these data support the notion that cladosporin interacts withInc.
Figure 4. Cladosporin Is Highly Selective for
PfKrs1, which Is Modulated in Part by Two Key
Active Site Residues
(A and B) Direct biochemical analysis of recombinant lysyl-
tRNA synthetase reveals that cladosporin has low nano-
molar inhibition (IC50 = 61 nM) against PfKrs1 (A, squares)
and high micromolar activity (IC50 > 20 mM) against human
Krs1 (B, squares). As a control, recombinant enzyme was
assayed under the same conditions but in the absence of
the tRNALys substrate (circles). Enzymatic data were from
at least two independent assays performed in triplicate
and expressed as means ± SD. A nonlinear regression
curve fit is shown for each.
(C) Superimposed structures of cladosporin (green) and
ATP (cyan) docked to the yeast homology model (gray).
Oxygen and nitrogen atoms are colored red and blue,
respectively, in all molecules. Cladosporin is predicted to
bind in the ATP-binding pocket of the yeast homology
model with the isocoumarin moiety located in the same
region as the adenine of ATP. Also, cladosporin’s pyrane
moiety superimposes between the sugar and the phos-
phate of ATP and projects toward Gln324 and Thr340. The
two hydroxy groups of cladosporin are predicted to form
hydrogen bonds with Asn335 and Glu328 (dotted lines;
bond length label given in A˚).
(D) ScKrs1-Gln324Val mutant (IC50 = 28 mM; squares) and
ScKrs1-Thr340Ser mutant (IC50 = 16 mM; diamonds)
mimic the differences in the Plasmodium ATP pocket and
significantly increase the potency of cladosporin
compared to wild-type S. cerevisiae strain (IC50 = 163 mM;
triangles). The double mutant, ScKrs1-Gln324Val/
Thr340Ser (IC50 = 4 mM; circles), which more closely
resembles PfKrs1, is 41-fold more sensitive to cladosporin. See also Figure S4. Enzymatic data were from at least two independent assays performed in triplicate
and expressed as means ± SD. A nonlinear regression curve fit is shown for each.
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a similar mode of binding to ATP.
To further understand the basis of cladosporin selectivity, the
amino acid residues of the ATP-binding pocket were compared
to those in Krs1 of other species (Figure S4C). While the majority
of amino acid residues in the binding pocket were highly
conserved, a clear divergence existed at two amino acid posi-
tions corresponding to S. cerevisiae residues Gln324 and
Thr340 (Table 2). In Plasmodium spp., these positions are occu-
pied by a valine and serine residue, respectively. Based on the
identity of the Plasmodium amino acid residues, smaller side
chains are favored, presumably due to decreased steric
hindrance. Additionally, a hydrophobic residue at position 324
also appears favorable for cladosporin binding.
Despite being separated by 15 amino acids in the primary
sequence, the homology model predicted that these residues
were juxtaposed in the active site (Figure S4D). The docking
model also predicts that the pyrane moiety of cladosporin points
toward both of these residues and that Thr340 resides at an inti-
mate distance of 3.7 A˚ (Figure 4C and Figure S4D). Extending the
comparison to other eukaryotic and prokaryotic pathogens with
Krs1 orthologs, a clear correlation exists between cladosporin
activity and the identity of the amino acids at these two key posi-
tions in the ATP-binding pocket (Table 2). The trend predicts
a significant loss in cladosporin potency whenever a bulkier
residue (replacement of serine with threonine) is present at posi-
tion 340. If this mutation is accompanied by a modestly more
bulky and polar residue at position 324 (valine to glutamine orCell Hasparagine), then an even more significant decrease in activity
is observed. The presence of a methionine at position 340 in
bacteria species, which would likely impose an even greater
steric hindrance than threonine, leads to the most significant
loss in cladosporin potency.
To validate whether ScKrs1 positions 324 and 340 are signifi-
cant factors in cladosporin selectivity and specificity, these posi-
tions were mutated in yeast to mimic those residues found in
Plasmodium spp. Substantial increases in cladosporin potency
were observed for both mutations. The single mutation
Gln324Val produced a 5.7-fold increase in cladosporin sensi-
tivity, whereas an even more pronounced increase by 10.4-fold
was observed for the Thr340Ser mutant (Figure 4D). As
expected, the double mutant Gln324Val/Thr340Ser led to an
even greater sensitization of yeast to cladosporin (38.7-fold
increase), as the active site of this mutant more closely resem-
bled that in Plasmodium spp. (Figure 4D). Finally, because
mutating two residues might alter the efficiency of the active
site, we replaced the entire yeast aminoacylation domain with
those from either human or P. falciparum (Figure 5A). These
strains were engineered to be dependent on the hybrid synthe-
tases, and all showed normal growth (Figure 5B). However, the
S. cerevisiae strain bearing the P. falciparum hybrid synthetase
showed a 1,000-fold increase in sensitivity to cladosporin (IC50
from >200 mM to 0.17 mM, Figure 5C). In contrast, the strains
bearing the human or yeast synthetases showed little change
in cladosporin sensitivity (Figure 5C). These data demonstrate
that the conformation of the aminoacylation domain rendersost & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevier Inc. 659
Table 2. Summary of AminoAcidConservation at KeyResidues in
the ATP Pocket of Krs1 and Corresponding IC50 Value of
Cladosporin
Organism
Cladosporin Inhibition
Key Active Site
Residuesa
IC50 (mM)
MICb
(mg/ml)
Position
324
Position
340
Plasmodium
falciparumc
0.04–0.08 Val Ser
Plasmodium
yoeliid
0.04 Val Ser
Trypanosoma
brucei
2.05 Val Thr
Leishmania
donovani
2.56 Val Thr
Toxoplasma
gondii
2.63 Asn Ala
Homo sapiens >10 Gln Thr
Saccharomyces
cerevisiae
30–110 Gln Thr
Escherichia coli >100 Asn Met
Bacillus
stearothermophilus
>100 Val Met
aAmino acid identity at homologous positions toScKrs1 residues 324 and
340 based on primary sequence alignments (see also Figure S4).
bMinimal inhibitory concentrations of cladosporin reported by Anke
(1979).
cSYBR Green proliferation assay of blood-stage parasites.
dHigh-content imaging of liver-stage parasites.
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and that lysyl-tRNA synthetase is the primary target of
cladosporin.
DISCUSSION
Cell-based screening has recently been shown to be an attrac-
tive way to find new leads for malaria drug development
(Gamo et al., 2010; Guiguemde et al., 2010; Plouffe et al.,
2008). In this respect, cladosporin could be an attractive lead,
given the species selectivity and potent nanomolar activity
against liver-stage parasites. Unfortunately, cladosporin
possesses poor oral bioavailability, a key requirement for an anti-
malarial. Therein lies a key disadvantage of the cell-based lead-
finding approach—if an initial hit is chemically intractable and the
target is not known, there may be no path forward. However, if
a chemically validated target can be discovered, then a more
focused and extensive lead-finding biochemical screen can be
readily initiated.
Methodological choices for finding targets in malaria parasites
have been traditionally limited. Cheminformatic predictions
based on historical screening data against different biochemical
targets (Gamo et al., 2010) and/or in silico docking typically only
creates hypotheses, and extensive, time-consuming experimen-
tation is required for confirmation. Affinity chromatography,
a method by which an inhibitor is immobilized to resin and incu-
bated with cell lysate to recover the molecular target, has been
used with limited success (Kato et al., 2008; Knockaert et al.,660 Cell Host & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevier2000). However, nonspecific binding, variable parasite protein
target abundance (1,000-fold differences in protein abundance
have been observed), and limitations in generating enough para-
site lysate for analysis make this a challenging approach. Thus,
evolution of drug-resistant parasites combined with genome
scanning (Dharia et al., 2009) is our preferred method for discov-
ering the target of antimalarials (McNamara and Winzeler, 2011;
Meister et al., 2011; Nam et al., 2011; Rottmann et al., 2010).
Nevertheless, some ambiguity often remains. Specifically,
more than one gene may be mutated, or in some cases, resis-
tance is conferred by a copy number variant encompassing
several genes. The use of yeast deletion strains to complement
the parasite evolution studies provides a powerful method of
confirmation. However, an inherent disadvantage of genetic
methods in both yeast and parasites is that only a resistance
mechanism may be revealed, and thus additional experiments
will always be necessary to validate the mechanism of action.
While it is possible that the amplification in lysyl-tRNA synthe-
tase only confers resistance to cladosporin, or that cladosporin
affects its killing through a different mechanism than by inhibiting
lysyl-tRNA synthetase in P. falciparum, our biochemical
evidence suggests that lysyl-tRNA synthetase is the primary
target of cladosporin. Recent evidence suggests that human
Krs1 has diverse biological roles beyond protein synthesis.
Among these functions, it is secreted as a proinflammatory cyto-
kine (Park et al., 2005) and is an integral component of a multi-
meric protein complex that affects regulatory signal pathways
(reviewed in Park et al., 2010). The large therapeutic window
between species makes inhibition of human Krs1 a minor
concern. However, it is not known whether these same diverse
functions are conserved inPlasmodium spp. Therefore, it is pres-
ently unclear if specifically targeting PfKrs1 and/or potential
components in these putative pathways makes this enzyme
a more desirable parasite target than other AARSs.
Aside from the noncanonical functions, selective inhibition of
the protein translational function of PfKrs1 has obvious value
because of the significant parasite proliferation during both liver-
and blood-stage infections. Indeed, AARSs have recently gained
recognition as desirable targets in antibacterial drug discovery
programs (Hurdle et al., 2005). For instance, mupirocin has
been shown to be a selective inhibitor of bacterial isoleucyl-
tRNA synthetase (Hughes andMellows, 1980; Sheng and Zhang,
2011), and a series of diaryl diamines specifically target Trypano-
soma brucei methionyl-tRNA synthetase (Shibata et al., 2011).
Also, a broad-spectrum inhibitor of fungal leucyl-tRNA synthe-
tases, AN2690, is in development for the treatment of onycho-
mycosis (Rock et al., 2007). However, targeting the AARS of an
invasive micro-organism without inhibiting the human counter-
part is a major challenge in drug discovery. Unlike the highly
divergent prokaryotes, eukaryotic pathogens such as fungus
(Candida spp.) and apicomplexan parasites (Plasmodium, Toxo-
plasma, and Trypanosoma spp.) generally have higher conserva-
tion with the homologous human AARS. Moreover, the lack of
three-dimensional structures from some eukaryotic pathogens
limits rational structure-based drug design to help identify and
exploit differences. Despite this, we show here that selective
eukaryotic AARS inhibitors can be achieved, opening the door
for target-based drug discovery efforts focused on lysyl-tRNA
synthetase. This in turn may lead to small molecules with theInc.
Figure 5. Yeast Cells Dependent on
Chimeric Lysyl-tRNA Synthetases Exhibit
Wild-Type Growth Kinetics but Show Differ-
ential Sensitivity to Cladosporin
(A) The homology model of ScKrs1 with clado-
sporin docked into the ATP binding site (asterisk).
Amino acids 1–220 corresponding to the tRNA-
binding domain are colored black, whereas resi-
dues beyond 220, which correspond to the
aminoacylation domain, are shown in color.
(B) Growth curves of yeast cells solely dependent
on heterologous, chimeric lysyl-tRNA synthetases
with aminoacylation domains of the indicated
species.
(C) Cladosporin dose-response curves of yeast
cells solely dependent on heterologous, chimeric lysyl-tRNA synthetases with aminoacylation domains of the indicated species. Data for (B) and (C) were
collected using the optical density assay and are a representation of triplicate experiments. The independent data points for each experiment are shown. In (C),
a nonlinear regression curve fit was performed on the means ± SD of these data.
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global eradication efforts.
EXPERIMENTAL PROCEDURES
HIP Profiling
Cladosporin was tested in three independent HIP experiments at 110 mM (two
times) and 150 mM (one time). Each experiment identified the krs1/KRS1 strain
as the most sensitive strain. The experimental execution and processing of
results were based on previous protocols (Pierce et al., 2007). The HIP assay
was performed in 24-well plates with 1,600 ml of YPD per well. Per experiment,
cladosporin was tested in two wells and compared to eight wells with DMSO.
At the beginning of each experiment, 100 ml per well of a 1.5 OD600/ml log
phase preculture comprising all strains of the heterozygous deletion collection
strains were added (OpenBiosystems, part numbers YSC1056). Plates were
incubated for 16 hr in a robotic shaking incubator at 30C/55 RPM, allowing
for approximately five doublings and then a robotic system back-diluted
50 ml/well into fresh medium with compound. This procedure was repeated
two more times until the yeast had doubled 20 times. The HIP pool construc-
tion, gDNA extraction, hybridization procedure, and calculation of sensitivity
scores were based on the methods published by Pierce et al. (Pierce et al.,
2007). In addition to the sensitivity score, for each gene, a z score was
calculated from the TAG4 microarray intensities by taking the logarithm of
the ratio of mean experiment versus mean control tag-averaged intensities.
The z scores of all genes were then robustly normalized experiment- and
gene-wise.
S. cerevisiae Aminoacyl-tRNA Synthetase Overexpression
Lysyl-tRNA synthetase (KRS1), isoleucyl-tRNA synthetase (IlS1), glutamyl-
tRNA synthetase (GLN4), and threonyl-tRNA synthetase (THS1) were
obtained from the previously characterized yeast GAL overexpression collec-
tion (Gelperin et al., 2005) (OpenBiosystems, part numbers YSC3870).
Cells were grown in synthetic medium supplemented with 2% galactose
and serial dilutions of cladosporin (200 mM max concentration, 3:1 dilution).
DMSO was normalized to 2%. Dose-response curves were calculated by
taking the 20 hr OD600 measurements and applying a logistic regression
curve fit.
Selection of Drug-Resistant S. cerevisiae
Strain BY4743D8, derived from BY4741 but deleted for eight genes involved in
drug resistance (efflux pumps, SNQ2, PDR5, YOR1; transcription factors,
PDR1, PDR2, PDR3, YAP1, YRM1) was incubated in 2.5% ethylmethanesulfo-
nate until only 50%of the cells formed colonies. A total of 23 107mutagenized
CMB970 cells were plated on two 14 cm dishes with synthetic complete
medium (0.7 g/l Difco Yeast Nitrogen Basewithout amino acids, 0.79 g/l MPbio
CSM amino acid mixture, 2% glucose) containing 50 mM cladosporin. AfterCell H4 days, 37 resistant colonies appeared. Resistance was confirmed by re-
streaking on 50 mM cladosporin. Genomic DNA was extracted (YeaStar
Genomic DNA Extraction Kit, Zymo Research), and the KRS1 gene including
promoter and terminator was sequenced (P1, CCTTACCTGAAGAGAAGG;
P2, GGTCAAGGAGATCACTGG; P3, CATCCCTTATCCCTTCTC; P4, CTCGA
CACCAACGATATC). Of these 37, ten colonies contained nonsynonymous
mutations in the KRS1 open reading frame. To distinguish between recessive
and dominant mutations, the ten strains were crossed with an isogenic wild-
type strain of opposite mating type and resistance confirmed by restreaking
on 50 mM cladosporin. All ten strains resulted in resistant diploids. To exclude
secondary mutations, KRS1 genes bearing three different mutations were
cloned into the SmaI and KpnI sites of the single copy pRS416 plasmid by
PCR amplification with primers, containing restriction sites at their 50 ends
(KRS1-SmaI, ATAATACCCGGGACCCATGAGCACAATAG; and KRS1-KpnI,
ATAATAGGTACCAGCGTATAGCACATCCAC) and transformed into clado-
sporin-sensitive BY4741 yeast. Resistance was confirmed by recording
dose-response curves in YPD medium with serial dilutions of cladosporin
(200 mM max concentration, 3:1 dilution). DMSO was normalized to 2%.
Curves were calculated by taking the 16 hr OD600 measurements and applying
a logistic regression curve fit.
Generation and Assay of Mutant KRS Lines in Yeast
S. cerevisiae KRS1wild-type genewas cloned into a pRS416 low copy number
plasmid. Single mutations were introduced by site-directed mutagenesis, and
the double mutant was generated by excising the 623 bp fragment containing
the Gln324Val mutation and cloning it between the EcoRI sites of the
Thr340Ser-containing plasmid. The resulting plasmids were verified by direct
DNA sequencing, transformed into KRS1/krs1 heterozygous deletion mutants,
sporulated, and the tetrads dissected. Selecting for uracil auxotrophy and
G418 resistance identified colonies exclusively dependent on the plasmid en-
coding mutant KRS1. IC50 values were determined by testing growth of four
independent colonies in SD-ura medium with 12-point serial dilutions at a dilu-
tion factor of 3. The top concentration of cladosporin was 200 uM and resulted
in a final DMSO concentration of 2%. Growth was monitored by reading OD600
values over 24 hr, and these data were fit to a nonlinear regression by Prism to
calculate the IC50 value.
Selection of Drug-Resistant Malaria Parasites
Cladosporin-resistant parasites were selected using the protocol described in
Rottmann et al. (Rottmann et al., 2010). In brief, clonal Dd2 parasites were es-
tablished in triplicate flasks and evolved independently. Drug challenge was
initiated at the IC50 value for cladosporin (40 nM) and increased in 10–40 nM
steps. The continuous exposure and challenge to sublethal concentrations
of inhibitor were carried out for 2 months, with final drug concentration
between 380 and 400 nM. Clonal cladosporin-resistant clones were selected
by limiting dilution using complete media supplemented with 340 nM clado-
sporin. Each clone was tested against a panel of antimalarial compounds
(Table S4).ost & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevier Inc. 661
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Genomic DNA samples, extracted from cladosporin-sensitive and clado-
sporin-resistant clones, were digested, labeled, and analyzed as previously
described by Dharia et al. (Dharia et al., 2009). Briefly, 15 mg of digested biotin
end-labeled genomic DNAwas hybridized to a custom high-density tiling array
(Pftiling). PfGenominator version 2.0 (freely available at http://www.scripps.
edu/winzeler/software/) was used to perform a comparative genomic analysis
to detect hybridization differences between the parental Dd2 clone and each
of the independently derived cladosporin-resistant clones. Modular analyses
were performed to identify copy number variation and single nucleotide poly-
morphism (SNP) events. A p value of cutoff <1 3 108 was enforced on the
SNP analysis to filter out false positives, and a probe-by-probe analysis was
performed on each SNP to validate its likelihood.
Metabolic Labeling with [35S]-Methionine/Cysteine for Protein
Synthesis Inhibition Studies
A metabolic labeling assay was performed according to the protocol
described in Rottmann et al. (Rottmann et al., 2010). For more information,
refer to the Supplemental Experimental Procedures.
Molecular Modeling
Structural alignment of the X-ray crystal structures of human (Protein Data
Bank [PDB] ID 3BJU) and bacterial lysyl-tRNA synthetases (PDB ID 1BBU
and 3E9H) using ICM software (Molsoft, LLC) revealed a high degree of simi-
larity (see Figure S4). The yeast homology model was built using theMOE soft-
ware (Chemical Computing Group). The human lysyl-tRNA synthetase X-ray
structure showed the greatest amino acid conservation to the yeast sequence
and was therefore selected as the template for the yeast homologymodel. The
homology model was built using MOE default parameters. Prior to docking
studies with cladosporin, a model for the binding of ATP in the yeast protein
was created. ATP was manually placed within the yeast homology model,
and the protein side chains were minimized in order to best accommodate
this compound. Cladosporin was docked in this protein using Glide SP (Schro¨-
dinger, LLC) and refined using the MM/GBSA method implemented in Prime
(Schro¨dinger, LLC).
Cloning and Expression of Plasmodium Lysyl-tRNA Synthetase
The sequence of the lysyl-tRNA synthetase (PF13_0262) was optimized for
E. coli codon usage and synthesized in pUCminus vector (1st Base). The
gene was subcloned into pET-28a(+) expression vector (Novagen) using
BamHI and EcoRI sites, and transformed into E. coli Tuner (DE3) cells (Nova-
gen). Of 2xYT media, 2 L containing 50 mg/ml kanamycin was inoculated with
20 ml of overnight culture and grown at 37C. Expression was induced with
0.1 mM IPTG at A600 = 0.8 and incubated for 24 hr at 13
C. The cells were
harvested by centrifugation at 6,000 rpm for 10 min and frozen at 80C.
Purification of Plasmodium Lysyl-tRNA Synthetase
Frozen cell pellets were thawed and resuspended in 60 ml cold lysis buffer
(20 mM Tris HCl [pH 8.0], 500 mM NaCl, 0.5 mM TCEP) supplemented with
0.01% SDS and a protease inhibitor tablet (Roche Diagnostics). Cells were
lysed by sonication, and the crude lysate was centrifuged (22,000 g, 1 hr at
4C). The supernatant was clarified through a 0.22 mm filter (Millipore) and
loaded onto a Ni-affinity column. The column was washed with 10 column
volumes wash buffer (20 mM Tris [pH 8.0], 500 mM NaCl, 50 mM imidazole,
and 0.5 mM TCEP) and the protein eluted with a gradient profile of 50–
500 mM imidazole over 20 column volumes. The protein-containing fractions
were dialyzed against low-salt buffer (20 mM Tris [pH 8.0], 100 mM NaCl,
and 0.5 mM TCEP) and loaded to a MonoQ 5/50GL column (GE Healthcare).
The column was washed with 4 column volumes of wash buffer 2 (20 mM
Tris [pH 8.0], 150 mM NaCl, 0.5 mM TCEP). A shallow gradient elution was
carried out with 150–1,000 mM NaCl over 50 column volumes. A final purifica-
tion step was repeated with the Ni-affinity column. The concentration of the
eluent-containing target protein was measured by absorbance at 280 nm
with ε = 41,780 M1 cm1.
Lysyl-tRNA Synthetase Activity Assay
Purified recombinant human enzyme was purchased from Origene (catalog
number TP300311). Enzymatic aminoacylation by lysyl-tRNA synthetase662 Cell Host & Microbe 11, 654–663, June 14, 2012 ª2012 Elsevierwas assayedwith the Transcreener AMP assay system (BellBrook) in a Corning
384-well black plate. The PftRNALys substrate was chemically synthesized
(Trilink). The assay was performed in a 10 ml volume containing either
250 nM of Plasmodium purified enzyme or 30 nM of human lysyl-tRNA synthe-
tase (OriGene) in 40 mM HEPES (pH 7.5), 1 mM DTT, 40 mM ATP, 10 mM
PftRNALys, 8 mM MgCl2, and 40 mM L-lysine. Reagent mixing was performed
on orbital shaker for one minute at 900 rpm, followed by incubation at RT
for 4 hr. Enzymatic activity was terminated by the addition of an equal volume
(10 ml) of detection reagent and yielded a final concentration of 0.53 stop
buffer, 1 nM AMP-Alexa633 tracer, and 2.5 mg/ml ADP antibody. Fluorescence
polarization measurements were performed on the Infinite M1000 plate reader
(Tecan) using a 635 nm excitation and 680 nm emission (20 nm bandwidth)
filter settings. IC50 values were determined by subtracting the background
activity and performing nonlinear regression with Prism (GraphPad).
Construction of Hybrid Synthetase Yeast Strains
Protein sequences of Homo sapiens (NM_001130089) and P. falciparum
lysyl-tRNA synthetase (PF13_0262) were aligned with S. cerevisiae Krs1
sequence. The first 220 ScKrs1 amino acids where taken (tRNA binding
domain) and then fused to the aminoacylation domains for the two respective
sequences. These hybrid protein sequences were back-translated into DNA
using yeast codon usage, and synthetic DNA fragments were created with
a SmaI site at the 30 end, 332 bp of S. cerevisiae KRS1 promoter sequence,
the hybrid KRS1 sequence, 206 bp of S. cerevisiae KRS1 terminator
sequence, and a KpnI site. As a control, the same construct was generated
using the full-length S. cerevisiae KRS1 sequence. The DNA fragments where
then cloned into the cloning site of pBYIntURA plasmids using the SmaI and
KpnI sites, linearized with BstX1, and transformed into the heterozygous
BY4743 KRS1/krs1::kanMX4 (ura3D) strain where the constructs integrated
into the TRP1 locus by selecting on medium lacking uracil. Transformants
were verified by analytical PCR, sporulated, and dissected. Germinating
spores were further analyzed for the integration of the plasmid in the TRP1
locus and presence of the KanMX deletion by analytical PCR. Integrity of
the integrated lysyl-tRNA synthetase constructs was verified by sequencing.
Growth kinetics of the strains were assessed by measuring OD600 values in
hourly intervals on a robotic system in 96-well plates. Sensitivity against
cladosporin was tested by growing the stains in serially diluted compound
as described previously.
Additional methods are provided in the Supplemental Information.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, five tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.chom.2012.04.015.
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